Vasa Therapeutics is a startup based in the United States, most recent round Seed.
Based in the United States, Vasa Therapeutics is a startup. Its most recent tracked round is Seed.
Vasa Therapeutics is a biopharmaceutical company developing therapeutics that target the pathophysiology of cardiovascular aging. Its pipeline includes VS-041, a narrow‑spectrum MMP‑2/9 inhibitor in development for heart failure with preserved ejection fraction (HFpEF), and apelin analog programs targeting peripheral artery disease, neuromuscular disorders and sarcopenia.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.